Trevi Therapeutics appoints David Hastings as CFO effective January 6, 2026

Trevi Therapeutics, Inc.

David Hastings previously served as CFO of Arbutus Biopharma (June 2018–March 2025).
Base salary set at $522,000; annual bonus target up to 40% of base salary.
Receives option to purchase 375,000 shares, vesting 25% on first anniversary and monthly thereafter.
Eligible for separation benefits under the Executive Separation Benefits and Retention Plan.
Standard indemnification agreement to be entered with the company.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.